Delivery Order SPE2DB25D3012-SPE2DB25FXANW
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets in quantities of seven units. This firm fixed price delivery order, valued at $32,489.92, represents a competitive award with no set-aside designation and is scheduled for completion by September 24, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibrance 75 mg tablets in a quantity of seven units, with a ceiling value of $32,495.84. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for ultimate completion on October 8, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7s) on August 26, 2025, with an ultimate completion date of September 17, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ibrance 100 mg tablets (quantity 7) with a ceiling value of $8,122.48. This is a firm fixed price delivery order with an ultimate completion date of October 17, 2025. The award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was competitively awarded with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, supporting the federal government's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units, with a contract ceiling value of $8,123.96. This competitively awarded, firm fixed-price delivery order is set to be completed by September 24, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 100 mg tablets (quantity 7s) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with a completion date of September 30, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ibrance 100 mg capsules (21-count packages) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which is expected to be completed by June 24, 2025, carries no set-aside designation and represents a competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXANWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 100 mg tablets in 7-count packaging, with a contract ceiling value of $24,367.44 and completion date of October 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with the federal government. The place of performance is the company's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen demonstrates consistent capability to fulfill federal requirements across multiple therapeutic domains through competitively awarded contracts with the DLA and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.4k | 9/26/25 |